Addendum
Ublituximab (multiple sclerosis) – Addendum to Project A24-13
Report documents
-
Addendum
Ublituximab (multiple sclerosis) – Addendum to Project A24-13
Dossier assessment
Indication:
Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
Result of dossier assessment:
- Men who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: proof of considerable added benefit
- Women who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
- Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
01-08-2024 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A24-68
- Commission
- Commission awarded on 11.06.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-68_en
Connected Projects
-
Dossier assessment
Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed